ReviewIndian journal of ophthalmology2026
Prostaglandin analog therapy challenges and innovation in glaucoma therapeutics.
Review in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma management primarily relies on prostaglandin analogs (PGAs) for effective intraocular pressure reduction. However, chronic PGA use frequently leads to ocular and periocular side effects such as conjunctival hyperemia, eyelash growth, and irreversible iris pigmentation, significantly affecting patient compliance and quality of life. These adverse effects are driven by molecular mechanisms involving receptor-mediated signaling and modulation of the extracellular matrix, with varying severities depending on the specific PGA and the presence of preservatives. Such side effects significantly impact patient compliance and quality of life, necessitating a comprehensive understanding and alternative treatment strategies. This review explores non-PGA alternatives, such as Rho kinase inhibitors, adenosine receptor agonists, and EP2/EP3 receptor agonists, which offer distinct mechanisms of action and potentially improved tolerability profiles. Future directions highlight the importance of personalized medicine, leveraging genetic insights to tailor treatments and minimize adverse reactions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.